continuous versus rapid infusion of albumin on the clinical outcomes of pediatric undergoing liver transplantation

continuous versus rapid infusion of albumin on the clinical outcomes of pediatric undergoing liver transplantation, a randomized clinical trial.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120731010453N5

Enrollment

Registered

2023-07-04

Start date

2023-07-01

Completion date

Unknown

Last updated

2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver transplantation. Other complications of liver transplant

Interventions

Intervention 1: Intervention group: They receive albumin at a dose of 0.5 to 1 g/kg slowly over 180 minutes. Intervention 2: Control group: They receive albumin at a dose of 0.5 to 1 g/kg rapidly for

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: ll patients which candidate to liver transplant younger than 18 years old

Exclusion criteria

Exclusion criteria: Re-transplantation simultaneous liver and kidney transplantation Hemorrhagic shock after liver transplantation during hospitalization known Hypersensitivity to albumin

Design outcomes

Primary

Measure	Time frame
Albumin level after transplantation. Timepoint: during hospitalization. Method of measurement: By measuring plasma level of albumin.;24-hour urine volume. Timepoint: During hospitalization. Method of measurement: By reviewing patient information.	—

Secondary

Measure	Time frame
Required dose of intravenous or oral diuretic after transplantation. Timepoint: during hospitalization. Method of measurement: Based on the drug chart.;The required dose of inotropes and vasopressors after liver transplantation. Timepoint: during hospitalization. Method of measurement: Based on the drug chart.;Hospital and ICU stay. Timepoint: During hospital and ICU stay. Method of measurement: By reviewing patient information.;Duration of ventilation. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Hemodynamic status and patient resuscitation after shock. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Status of transplanted liver. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Death rate. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Incidence of post-transplant infections. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;The incidence and stability of abdominal ascites. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Pleural effusion. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Incidence of portal vein thrombosis. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Leakage rate after transplant. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.	—

Measure

Time frame

Required dose of intravenous or oral diuretic after transplantation. Timepoint: during hospitalization. Method of measurement: Based on the drug chart.;The required dose of inotropes and vasopressors after liver transplantation. Timepoint: during hospitalization. Method of measurement: Based on the drug chart.;Hospital and ICU stay. Timepoint: During hospital and ICU stay. Method of measurement: By reviewing patient information.;Duration of ventilation. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Hemodynamic status and patient resuscitation after shock. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Status of transplanted liver. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Death rate. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Incidence of post-transplant infections. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;The incidence and stability of abdominal ascites. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Pleural effusion. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Incidence of portal vein thrombosis. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.;Leakage rate after transplant. Timepoint: during hospitalization. Method of measurement: By reviewing patient information.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Shafiekhani

Shiraz University of Medical Sciences

mojtabashafiekhani@gmail.com+98 71 3242 4255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026